Brokers Offer Predictions for HRTX Q2 Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Northland Capmk issued their Q2 2025 earnings per share estimates for shares of Heron Therapeutics in a report released on Tuesday, May 6th. Northland Capmk analyst C. Byrnes forecasts that the biotechnology company will earn ($0.01) per share for the quarter. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share. Northland Capmk also issued estimates for Heron Therapeutics’ FY2025 earnings at $0.01 EPS.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. The company had revenue of $38.90 million during the quarter, compared to analyst estimates of $37.08 million.

Other research analysts also recently issued research reports about the stock. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a report on Friday, April 11th. StockNews.com cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 8th.

Heron Therapeutics Trading Down 3.8 %

Shares of Heron Therapeutics stock opened at $2.18 on Thursday. The firm has a fifty day simple moving average of $2.19 and a 200-day simple moving average of $1.82. The stock has a market capitalization of $331.75 million, a price-to-earnings ratio of -12.08 and a beta of 1.33. Heron Therapeutics has a 1-year low of $1.04 and a 1-year high of $3.93.

Hedge Funds Weigh In On Heron Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nicolet Advisory Services LLC bought a new stake in Heron Therapeutics in the 4th quarter valued at $25,000. RFP Financial Group LLC bought a new stake in shares of Heron Therapeutics in the first quarter valued at about $26,000. Argent Advisors Inc. bought a new stake in shares of Heron Therapeutics in the fourth quarter valued at about $31,000. Focus Partners Wealth acquired a new stake in Heron Therapeutics during the fourth quarter worth about $31,000. Finally, Valeo Financial Advisors LLC increased its stake in Heron Therapeutics by 34.1% during the first quarter. Valeo Financial Advisors LLC now owns 18,152 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 4,619 shares during the period. Institutional investors own 80.01% of the company’s stock.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.